Related Experiment Video
Updated: May 10, 2026

Microsurgical Venous Pouch Arterial-Bifurcation Aneurysms in the Rabbit Model: Technical Aspects
Published on: May 11, 2011
Bevacizumab-Associated Enterocutaneous Fistula: A Case Report and Management Review
Madison L Wallace1, Linda Akbarshahi2, Matthew Bond3
1Obstetrics and Gynecology, Medical College of Georgia, Augusta University, Athens, USA.
Bevacizumab therapy can rarely cause enterocutaneous fistula (ECF). This case report details the first patient with both ECF and colovaginal fistula after bevacizumab for cervical cancer, highlighting management needs.
Area of Science:
- Oncology
- Gastroenterology
- Gynecologic Oncology
Background:
- Bevacizumab is a monoclonal antibody used in cancer therapy.
- Enterocutaneous fistula (ECF) is a rare but serious complication of bevacizumab.
- Cervical cancer treatment can involve bevacizumab, particularly for recurrent cases.
More Related Videos
Related Concept Videos
Esophageal Perforation-II: Clinical Manifestations and Management
Clinical Manifestations:
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Endocarditis IV: Nursing Management

